102 related articles for article (PubMed ID: 28849826)
21. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
Ozols RF
Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
[TBL] [Abstract][Full Text] [Related]
22. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
[TBL] [Abstract][Full Text] [Related]
26. let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.
García-Vázquez R; Gallardo Rincón D; Ruiz-García E; Meneses García A; Hernández De La Cruz ON; Astudillo-De La Vega H; Isla-Ortiz D; Marchat LA; Salinas-Vera YM; Carlos-Reyes Á; López-González S; Ramos-Payan R; López-Camarillo C
Oncol Rep; 2018 Jun; 39(6):3086-3094. PubMed ID: 29658612
[TBL] [Abstract][Full Text] [Related]
27. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
28. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
Semin Oncol; 1994 Oct; 21(5 Suppl 8):34-8. PubMed ID: 7939761
[TBL] [Abstract][Full Text] [Related]
29. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
30. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
31. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
32. Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.
Marchetti C; De Felice F; Musella A; Palaia I; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Oncotarget; 2016 Sep; 7(36):58709-58715. PubMed ID: 27509061
[TBL] [Abstract][Full Text] [Related]
33. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
He Z; Shi Z; Sun W; Ma J; Xia J; Zhang X; Chen W; Huang J
Tumour Biol; 2016 Jun; 37(6):7809-21. PubMed ID: 26695149
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.
Zhu T; Liu CL; Zhang YF; Liu YH; Xu FP; Zu J; Zhang GC; Li XR; Liao N; Wang K
Breast Cancer Res Treat; 2016 Feb; 156(1):117-24. PubMed ID: 26936755
[TBL] [Abstract][Full Text] [Related]
35. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE; Beesley J; Paul J; Fereday S; Spurdle AB; Webb PM; Byth K; Marsh S; McLeod H; ; Harnett PR; Brown R; DeFazio A; Chenevix-Trench G
Clin Cancer Res; 2008 Sep; 14(17):5594-601. PubMed ID: 18765553
[TBL] [Abstract][Full Text] [Related]
36. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin and paclitaxel in ovarian cancer.
Ozols RF
Semin Oncol; 1995 Jun; 22(3 Suppl 6):78-83. PubMed ID: 7541158
[TBL] [Abstract][Full Text] [Related]
38. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
39. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
40. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]